New Prostate Cancer Treatment Kills Tumors, Wakes Immunity
A new treatment approach is targeting prostate tumors from two directions at once.
Researchers at Weill Cornell Medicine and the Cornell Duffield College of Engineering say engineered nanoparticles can kill prostate cancer cells directly while switching on the immune system's attack against the tumor.
The findings appear in a study published June 15 in Cancer Research, a journal of the American Association for Cancer Research.
What The New Prostate Cancer Study Found
Cornell Chronicle reported that the particles are made of amorphous silica, the same compound found in leafy greens and cereal grains.
Known as Cornell Prime dots, or C' dots, they were originally developed for medical imaging.
In mouse models of aggressive prostate cancer, the particles triggered several complete remissions of advanced tumors.
📰 Related: World's First AI-Designed Universal Vaccine Passes Human Trial at Cambridge
The particles work by pushing tumor cells into ferroptosis, a self-destruct process driven by runaway oxidation of fat molecules in cell membranes.
Researchers believe the particles pick up iron ions from the bloodstream and carry them into tumor cells, where the reaction accelerates.
Why The Immune System Response Matters Here
Beyond killing cells directly, the C' dots appear to convert the prostate tumor's immune environment from "cold" to "hot."
That shift means T cells, macrophages and other immune cells near the tumor switch from inactive or suppressive states into active antitumor roles.
Dr. Michelle Bradbury, director of the Molecular Imaging Innovations Institute at Weill Cornell Medicine, led the study.
She said a treatment that kills tumor cells while reshaping the immune microenvironment would represent a new clinical paradigm.
The work builds on a collaboration with co-corresponding author Ulrich Wiesner of Cornell's Duffield College of Engineering.
📰 Related: Scientists Discover a Brain "Switch" That Turns Off Anxiety — A Potential Treatment Revolution
The Numbers Behind The Survival Results
The most notable results came from survival experiments in mice with aggressive prostate cancer.
C' dots alone, and immunotherapy alone, each moderately extended survival compared with no treatment.
Combining the particles with immune checkpoint blockade produced complete or near-complete remissions in four of 10 mice, with indefinite survival in that group.
Adding a third treatment targeting tumor-associated macrophages, CSF-1R blockade, raised that figure to five of 10 complete remissions.
Bradbury said the team believes there is nothing else with such a strong, durable tumor-suppressing effect.
📰 Related: Pancreatic Cancer Breakthrough: New Drug Daraxonrasib Nearly Doubles Survival Rate
Targeting And Safety In Non-Prostate Tissue
The particles were directed to prostate tumor cells using a molecule that binds to PSMA, a protein on prostate cancer cell surfaces.
Even when particles briefly concentrated in other tissue, including the spleen, Cornell researchers found no sign of toxicity.
Study co-author Dr. Jedd Wolchok, director of the Parker Institute for Cancer Immunotherapy at Weill Cornell Medicine, said the combination could help unlock immunotherapy's potential in prostate cancer, where durable responses have historically been hard to achieve.
What Happens Next For C' Dots In Cancer Treatment
The C' dots have already advanced into clinical trials for image-guided surgery, giving researchers an existing safety record.
This study remains preclinical, conducted in mouse models rather than human patients.
The research was funded in part by the Department of Defense, the National Cancer Institute, and the Parker Institute for Cancer Immunotherapy.
The team is now studying the particles as a broader class of anticancer therapeutics, aiming to test safety and efficacy in human trials.
If those trials confirm the mouse results, the approach could give prostate cancer patients a new option beyond existing immunotherapies.
Key Takeaways
- Cornell researchers developed nanoparticles called C' dots that kill prostate tumor cells and activate immune response.
- The study was published June 15, 2026, in Cancer Research.
- C' dots trigger ferroptosis, a self-destruct process in tumor cells.
- Combining particles with immune checkpoint blockade produced 4 of 10 complete remissions in mice.
- Adding CSF-1R blockade raised that to 5 of 10 complete remissions.
- The particles target prostate cells via PSMA with no toxicity seen in other tissue.
Sources
Also Read
Health & Lifestyle Editor
Emma Rhodes covers public health, wellness, medical breakthroughs, and lifestyle trends. She is committed to reporting health news that is accurate, clear, and actionable.
